Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3 | P19429 | 1/20 | 0.61 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.61 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 9/20 | 0.42 |
| ▸ | ACHE | P22303 | 9/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798812 | 1.00 | TNNI3 (0.61) | TNNI3TNNT2TNNC1MEN1USP2 | |
| Hydrochloric Acid SCHEMBL7239186 | 0.77 | TNNI3 (0.60) | TNNI3TNNT2TNNC1MEN1USP2 | |
| Hydrochloric Acid SCHEMBL7240577 | 0.69 | CSNK2A2 (0.54) | TNNI3TNNT2TNNC1MEN1USP2 | |
| SCHEMBL11540737 | 0.68 | TNNI3 (0.33) | TNNI3TNNT2TNNC1MEN1USP2 | |
| SCHEMBL11637101 | 0.65 | ALDH1A1 (0.44) | RAB9ACSNK2A2CSNK2BCSNK2A1ACHE | |
| SCHEMBL11536506 | 0.64 | ACHE (0.34) | BCHEACHE | |
| SCHEMBL6946923 | 0.64 | ACHE (0.34) | TNNI3TNNT2TNNC1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL18096521 | 0.64 | CSNK2A2 (0.49) | TNNI3TNNT2TNNC1MEN1USP2 | |
| SCHEMBL7801316 | 0.64 | ACHE (0.41) | BCHEACHE | |
| SCHEMBL8739989 | 0.60 | CSNK2A2 (0.50) | CSNK2A2CSNK2BCSNK2A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117683-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2019-04-25 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| WO-2017060388-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2017-04-13 | — | — | WO | claimed |
| US-20170044590-A1 | METHODS FOR DETECTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF NOTRE DAME DU LAC | 2017-02-16 | — | — | US | claimed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | claimed |
| WO-2015042326-A2 | METHODS FOR DETECTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-03-26 | — | — | WO | claimed |
| EP-1792605-A1 | Use of at least a cationic cyanine derivative for use in hair dyeing, composition containg it process of treating keratinic fibres using the same composition, kit and use thereof | L'Oréal (FR) | 2007-06-06 | — | — | EP | claimed |
| EP-1509520-B1 | USE OF BENZO(C)QUINOLIZINIUM DERIVATIVES FOR THE TREATMENT OF DISEASES THAT ARE LINKED TO SMOOTH MUSCLE CELL CONSTRICTION | CENTRE NAT RECH SCIENT (FR) | 2006-11-22 | — | — | EP | claimed |
| US-20050176747-A1 | Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-08-11 | — | — | US | claimed |
| EP-1509520-A1 | USE OF BENZO(C)QUINOLIZINIUM DERIVATIVES FOR THE TREATMENT OF DISEASES THAT ARE LINKED TO SMOOTH MUSCLE CELL CONSTRICTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-03-02 | — | — | EP | claimed |
| WO-2003104228-A1 | USE OF BENZO[C]QUINOLIZINIUM DERIVATIVES FOR THE TREATMENT OF DISEASES THAT ARE LINKED TO SMOOTH MUSCLE CELL CONSTRICTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2003-12-18 | — | — | WO | claimed |
| US-6630482-B1 | Cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2003-10-07 | — | — | US | claimed |
| EP-0937044-B1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NAT RECH SCIENT (FR) | 2002-01-30 | — | — | EP | claimed |
| EP-0937044-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1999-08-25 | — | — | EP | claimed |
| WO-1998005642-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-02-12 | — | — | WO | claimed |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| WO-1998005642-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-02-12 | — | — | WO | disclosed |
| WO-1998005642-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TNNI3 2327/4885TNNT2 3233/4885TNNC1 3911/4885 |
| US-20050176747-A1 | Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction | MYLK, MYLK2, TNNI3 | TNNI3 3/4885TNNT2 5/4885TNNC1 46/4885 |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | CFTR, MFAP1, CMA1 | TNNI3 3823/4885TNNT2 2308/4885TNNC1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.